| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01:05 | LIR Life Sciences ernennt Dr. Peter Singer zum wissenschaftlichen Berater | 1.428 | IR-WORLD | Vancouver, Kanada - 18. Dezember 2025 / IRW-Press / LIR Life Sciences Corp. (CSE: SKNY) (FWB: N790, WKN: A41QA9) ("LIR" oder das "Unternehmen") freut sich bekannt zu
geben, dass Dr. Peter Singer... ► Artikel lesen | |
| 09:46 | Teva Pharmaceutical Industries Ltd: Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea | 515 | GlobeNewswire (Europe) | According to the settlement agreement, the proposed biosimilar to Eylea (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circumstances
REYKJAVIK... ► Artikel lesen | |
| 07:00 | Neue Trump-Cannabis-Regulierung: Wie geht es jetzt mit Bioxyne, Canopy Growth und Tilray weiter? | Small- & Micro Cap Investment | |||
| Do | Telo Genomics Corp.: Telo Genomics Launches Retrospective Blood-Based MRD Study with University of Athens as Part of 2026 Multi-Center Validation Program | 383 | Newsfile | Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in diagnostic and prognostic innovation through advanced... ► Artikel lesen | |
| Do | Bavarian Nordic A/S: Bavarian Nordic Establishes Long-term Incentive Program for Members of Executive Management and Selected Employees | 376 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, December 18, 2025 - Bavarian Nordic A/S (OMX: BAVA) announced today that the Board of Directors has decided to establish a long-term incentive program for Executive Management... ► Artikel lesen | |
| Do | Galapagos NV: Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus | 306 | GlobeNewswire (Europe) | GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to placebo
In... ► Artikel lesen | |
| 00:02 | Lir Life Sciences Corp.: LIR Life Sciences Announces Appointment of Dr. Peter Singer as Scientific Advisor | 280 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / December 18, 2025 / LIR Life Sciences Corp. (CSE:SKNY)(Frankfurt:N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce that Dr. Peter Singer, a global... ► Artikel lesen | |
| 11:10 | Thiogenesis-Aktie: Hier liegen die großen Hoffnungen | 273 | sharedeals.de | Das kanadische Biotech-Unternehmen Thiogenesis Therapeutics treibt mit Nachdruck die Planungen mit seinem neuen Asset voran, einer Phase-3-Studie der nephropathischen Zystinose. Doch die Thiogenesis-Aktie... ► Artikel lesen | |
| 14:21 | EQS-Media: Lir Life Sciences Corp.: Strategischer Neuzugang: Ehemaliger WHO-Berater wird Scientific Advisor bei Lir Life Sciences | 267 | EQS Group (DE) | EQS-Media / 19.12.2025 / 14:18 CET/CEST
Lir Life Sciences Corp. (ISIN: CA50206C1005 | WKN: A41QA9), LIR oder das Unternehmen, freut sich bekannt zu geben, dass Dr. Peter Singer, ein internationaler... ► Artikel lesen | |
| 14:30 | BioMarin To Acquire Amicus Therapeutics For Around $4.8 Bln | 247 | AFX News | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN), a pharmaceutical company, Friday announced that it has entered into a definitive agreement to acquire Amicus Therapeutics (FOLD),... ► Artikel lesen | |
| Do | EQS-News: ABIVAX: Abivax to be Added to Nasdaq Biotechnology Index | 246 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Miscellaneous
Abivax to be Added to Nasdaq Biotechnology Index
18.12.2025 / 22:05 CET/CEST
The issuer is solely responsible for the content... ► Artikel lesen | |
| 13:10 | Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2 | 242 | GlobeNewswire (Europe) | MSD declines to exercise option for EVX-B2 developmentEvaxion is now able to out-license EVX-B2 to another partnerEvaxion maintains its strong belief in EVX-B2, which has shown to be protective against... ► Artikel lesen | |
| 09:36 | Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea | 229 | GlobeNewswire (Europe) | REYKJAVIK, Iceland and TEL AVIV, Israel and PARSIPPANY, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of... ► Artikel lesen | |
| 17:10 | Athira Pharma: Aktie knallt +170% nach NBC-Einstieg | 226 | sharedeals.de | Vorweihnachtliche Bescherung im No Brainer Club - und das am Fließband: Während Mitglieder noch mit dem Feiern der +167%-Rakete VYNE Therapeutics beschäftigt waren, schlug auch schon der nächste Volltreffer... ► Artikel lesen | |
| 08:58 | Aquaporin A/S: Aquaporin updates on strategic review and sets mid-and long-term financial targets | 213 | PR Newswire | Company announcementNo. 21/2025Inside information
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY... ► Artikel lesen |
| Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
|---|---|---|---|---|---|---|
| AMGEN | 280,40 | 8,13 | +2,90 % | 2,52 | 13.02.2026 | |
| RECORDATI | 48,380 | 1,30 | +2,69 % | 0,63 | 24.11.2025 | |
| STRYKER | 304,30 | 2,90 | +0,95 % | 0,88 | 31.12.2025 | |
| BIO-TECHNE | 49,600 | 0,27 | +0,54 % | 0,08 | 17.11.2025 | |
| REGENERON PHARMACEUTICALS | 654,20 | 3,04 | +0,46 % | 0,88 | 20.11.2025 | |
| BIOGEN | 148,75 | 0,00 | 0,00 % | |||
| ENZO BIOCHEM | 0,388 | 0,00 | 0,00 % | |||
| MYRIAD GENETICS | 5,650 | 0,00 | 0,00 % | |||
| TRANSGENE | 0,904 | 0,00 | 0,00 % | |||
| INOVIO PHARMACEUTICALS | 2,020 | 0,00 | 0,00 % |